<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913610</url>
  </required_header>
  <id_info>
    <org_study_id>B18-894</org_study_id>
    <secondary_id>DNDi-TYL-01</secondary_id>
    <nct_id>NCT04913610</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection</brief_title>
  <official_title>A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Drugs for Neglected Diseases initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onchocerciasis is a major public health problem in affected countries that causes&#xD;
      disease-induced disability, and overall loss of economic productivity. The purpose of this&#xD;
      study is to determine how safe and effective ABBV-4083 in combination with albendazole is in&#xD;
      treating participants with Onchocerciasis.&#xD;
&#xD;
      ABBV-4083 is an investigational drug being developed for the treatment of onchocerciasis.&#xD;
      This study is conducted in 2 parts. In part 1, participants are randomly assigned to 1 of 5&#xD;
      groups, called treatment arms to determine the most efficient treatment combination. Each&#xD;
      group receives a different treatment. In part 2, participants are randomly assigned to 1 of 4&#xD;
      treatment arms. Approximately 444 or 486 adult participants with a diagnosis of&#xD;
      onchocerciasis will be enrolled in approximately 2 sites in Democratic Republic of Congo.&#xD;
&#xD;
      Participants in Part 1 will receive different treatment combinations of ABBV-4083 and/or&#xD;
      albendazole and/or matching placebo capsules for 14 days. Participants in Part 2 will most&#xD;
      effective treatment combination determined in Part 1 for 14 days followed by ivermectin or&#xD;
      matching placebo capsules at Month 6. Duration of treatment is 24 months.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests and&#xD;
      checking for side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2021</start_date>
  <completion_date type="Anticipated">January 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Status of Each Live Female Adult Worm as Without Wolbachia Endobacteria</measure>
    <time_frame>6 Months</time_frame>
    <description>Status of each live female adult worm as without Wolbachia endobacteria or not, is assessed by immunohistology of nodules collected after nodulectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Status of Each Participant as Without Skin Microfilariae</measure>
    <time_frame>24 Months</time_frame>
    <description>Status of each participant as without skin microfilariae or not is assessed across all skin snips in each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Live Female Adult Worms per Participant</measure>
    <time_frame>24 Months</time_frame>
    <description>Percentage of live female adult worms per participant assessed by histological examination of all nodules collected after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Perentage of Live Female Adult Worms With Only Degenerated Embryos in Uterus per Participant</measure>
    <time_frame>24 Months</time_frame>
    <description>Percentage of live female adult worms with only degenerated embryos in uterus per participant is assessed by histological examination of nodules collected after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Live Female Adult Worms With Only Degenerated Embryos in the Uterus per Participant</measure>
    <time_frame>6 Months</time_frame>
    <description>Percentage of live female adult worms with only degenerated embryos in the uterus per participant after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Percentage of Live Female Adult Worms out of all Female Adult Worms per Participant</measure>
    <time_frame>6 Months</time_frame>
    <description>Percentage of live female adult worms out of all female adult worms per participant after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Absence of Microfilariae in Nodular Tissue per Participant</measure>
    <time_frame>6 Months</time_frame>
    <description>Absence of microfilariae in nodular tissue per participant after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Status of Each Participant as Without Skin Microfilariae or not</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Status of each participant as without skin microfilariae or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0)</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Skin microfilarial density is defined as the mean number of microfilariae/mg per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not</measure>
    <time_frame>6 Months</time_frame>
    <description>Status of each live adult worm as without Wolbachia endobacteria or not is assessed by polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Status of Each Participant as Without Skin Microfilariae or not</measure>
    <time_frame>18 Months</time_frame>
    <description>status of each participant as without skin microfilariae or not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Reduction in Skin Microfilarial Density Compared to Baseline (Week 0)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Skin microfilarial density is defined as the mean number of microfilariae/mg per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absence of Microfilariae in Nodular Tissue per Participant</measure>
    <time_frame>24 Months</time_frame>
    <description>Absence of microfilariae in nodular tissue per participant after nodulectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Status of Each Live Adult Female Worm as Without Wolbachia Endobacteria or not</measure>
    <time_frame>24 Months</time_frame>
    <description>Status of each live adult female worm as without Wolbachia endobacteria or not is assessed by immunohistology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Status of Each Live Adult Worm as Without Wolbachia Endobacteria or not</measure>
    <time_frame>24 Months</time_frame>
    <description>Status of each live adult worm as without Wolbachia endobacteria or not is assessed by polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by ABBV-4083 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-4083 + albendazole for 3 days followed by ABBV-4083 + placebo for albendazole for 4 days followed by placebo for ABBV-4083 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo for ABBV-4083 + albendazole for 7 days followed by placebo for ABBV-4083 for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active regimen from Part 1 followed by ivermectin at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active regimen from Part 1 followed by placebo for ivermectin at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive active regimen from Part 1 followed by placebo for ivermectin or matching placebo at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scenario 1: Participants will receive placebo for ABBV-4083 + placebo for albendazole followed by ivermectin at Month 6.&#xD;
Scenario 2: Participants will receive ABBV-4083 + placebo for albendazole for 7 days followed by placebo for ABBV-4083 for appropriate duration followed by ivermectin or matching placebo at Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-4083</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_label>Part 1: Arm E</arm_group_label>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_label>Part 2: Arm N</arm_group_label>
    <other_name>Tylamac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-4083</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_label>Part 1: Arm E</arm_group_label>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_label>Part 2: Arm N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Oral encapsulated tablets</description>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_label>Part 1: Arm E</arm_group_label>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <other_name>Zentel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Albendazole</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_label>Part 2: Arm N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ivermectin</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>Part 2: Arm L</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_label>Part 2: Arm N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Encapsulated Oral Tablet</description>
    <arm_group_label>Part 2: Arm K</arm_group_label>
    <arm_group_label>Part 2: Arm M</arm_group_label>
    <arm_group_label>Part 2: Arm N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Onchocerca volvulus infection at time of Screening:&#xD;
&#xD;
               -  Presence of at least one excisable subcutaneous nodule/ onchocercoma detected on&#xD;
                  palpation;&#xD;
&#xD;
               -  O. volvulus infection diagnosed by skin snip method: documented mfpositivity on&#xD;
                  skin assessment on at least 2 out of 4 skin snips.&#xD;
&#xD;
          -  Body weight &gt; 40 kg at Screening.&#xD;
&#xD;
          -  For women of child-bearing potential, acceptance of the requirement to use a highly&#xD;
             effective form of birth control from Day 0 until at least 1 month after the final&#xD;
             intake of study drug (Part 1: day 43; Part 2: 1 month after the administration of&#xD;
             ivermectin or matching placebo at the Month 6 visit). Choice of birth control method&#xD;
             must be clearly documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any studies other than purely observational studies within 3 months&#xD;
             prior to Screening, or during the trial, or within 5 times the half-life of the drug&#xD;
             tested in the previous clinical trial or is currently in the follow-up period for any&#xD;
             clinical trial.&#xD;
&#xD;
          -  Any vaccination within 4 weeks prior to investigational medicinal product (IMP)&#xD;
             administration.&#xD;
&#xD;
          -  Acute infection and/or febrile illness requiring therapy within 14 days prior to IMP&#xD;
             administration.&#xD;
&#xD;
          -  Administration of medication or herbal preparations as follows:&#xD;
&#xD;
               -  Administration of any medication (with the exception of diclofenac, paracetamol,&#xD;
                  ibuprofen and aspirin) or herbal preparation within 14 days prior to IMP&#xD;
                  administration;&#xD;
&#xD;
               -  Use of strong CYP3A inhibitors or inducers including but not limited to&#xD;
                  ritonavir, ketoconazole, rifampicin, phenytoin, phenobarbital, carbamazepine,&#xD;
                  cimetidine within 14 days or 10 half-lives, whichever is longer, prior to IMP&#xD;
                  administration;&#xD;
&#xD;
               -  Use of other drugs known to interact with albendazole i.e. praziquantel,&#xD;
                  theophylline or dexamethasone, within 14 days or 10 half-lives, whichever is&#xD;
                  longer, prior to IMP administration;&#xD;
&#xD;
               -  Antifilarial therapies, or medication that may have an antifilarial effect.&#xD;
&#xD;
          -  Requirement for and inability to avoid ivermectin during the first 6 months after IMP&#xD;
             administration. Requirement for albendazole during the first 28 days after IMP&#xD;
             administration or more than one dose per year thereafter given in MDA.&#xD;
&#xD;
          -  Presence of any of the following at Screening, that could interfere with the&#xD;
             objectives of the trial or the safety of the participant, in the opinion of the&#xD;
             Investigator:&#xD;
&#xD;
               -  Abnormal physical examination or laboratory findings;&#xD;
&#xD;
               -  Any clinically significant medical condition. Including, but not limited to&#xD;
                  significant acute or chronic liver or kidney condition or cardiovascular disease,&#xD;
                  active infection, current or previous epilepsy, known human immunodeficiency&#xD;
                  virus infection, disclosed by review of medical history or concomitant&#xD;
                  medication.&#xD;
&#xD;
          -  Ophthalmological history or conditions that could interfere with the objectives of the&#xD;
             trial or compromise the safety of the subject in the opinion of the Investigator,&#xD;
             assessed at Screening.&#xD;
&#xD;
          -  History of drug or alcohol abuse within 6 months prior to IMP administration.&#xD;
&#xD;
          -  Use of alcohol or drugs of abuse within 24 hours before IMP administration.&#xD;
&#xD;
          -  Clinically significant history of cardiac abnormality, and/or relevant pathological&#xD;
             abnormalities in the ECG in the screening period.&#xD;
&#xD;
          -  Abnormal laboratory test results at Screening.&#xD;
&#xD;
          -  History of severe drug allergy, non-allergic drug reactions, severe adverse reaction&#xD;
             to any drug, or multiple drug allergies.&#xD;
&#xD;
          -  Known hypersensitivity to any ingredient of the IMPs, including the active ingredient&#xD;
             of ABBV-4083, macrolides, albendazole or to ivermectin or to any medication used&#xD;
             during the study.&#xD;
&#xD;
        Blood donation within 8 weeks prior to Screening or blood transfusion received within 1&#xD;
        year prior to Screening.&#xD;
&#xD;
          -  Coincidental infection with high Loa loa load and/or Mansonella species or Wuchereria&#xD;
             bancrofti, based on positive laboratory test at Screening.&#xD;
&#xD;
          -  Current hyperreactive onchodermatitis or severe manifestation due to onchocerciasis.&#xD;
&#xD;
          -  Any other past or current condition that the Investigator feels would exclude the&#xD;
             participant from the study or place the subject at undue risk.&#xD;
&#xD;
          -  For women of child-bearing potential: pregnant, based on date of last menstrual&#xD;
             period, and pregnancy test prior to first intake of IMP, or breastfeeding.&#xD;
&#xD;
          -  Unwilling or unable to comply with the requirements of the study protocol for the&#xD;
             entire duration of the study, in the opinion of the Investigator.&#xD;
&#xD;
          -  Unable to participate in the study as per local law, if applicable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Specht, PhD</last_name>
    <phone>+41796981351</phone>
    <email>sspecht@dndi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Général de Référence de Kimpese</name>
      <address>
        <city>Kimpese</city>
        <state>Kongo Central</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Général de Référence de Masi-Manimba</name>
      <address>
        <city>Masi-Manimba</city>
        <state>Kwilu</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onchocerciasis</keyword>
  <keyword>Onchocerca volvulus</keyword>
  <keyword>River blindness</keyword>
  <keyword>ABBV-4083</keyword>
  <keyword>Tylamac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Intestinal Volvulus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

